FTC Requests Further Information on Potential Pfizer Takeover of Seagen
Demand comes among antitrust agency’s recent denial of Amgen’s Horizon buyout.
The Federal Trade Commission (FTC) has asked for more information on Pfizer’s proposed $43 billion takeover of Seagan, a biotechnology company. The request, which comes after the agency’s shutdown of Amgen’s attempt to purchase Horizon Therapeutics for $27.8 billion, has made investors skittish at the potential outcome.
Despite the request, Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024.
Reference: US FTC Seeks Additional Info on Pfizer's Proposed Takeover of Seagen. Reuters. July 14, 2023. Accessed July 17, 2023. https://www.reuters.com/markets/deals/us-ftc-seeks-additional-info-pfizers-proposed-takeover-seagen-2023-07-14/
Protecting Temperature-Sensitive Pharmaceuticals, Without Unnecessary Plastic Waste
March 24th 2025Advances in the life sciences are driving a significant increase in the number of temperature-sensitive pharmaceuticals. The packaging industry is meeting the moment with advances of its own, including high-performance, environmentally-friendly materials that allow life science companies meet stringent thermal requirements and ambitious CO2e reduction goals. In this episode, TemperPack’s CEO Peter Wells shares insights from working with life sciences to move to certified biobased, home compostable, and curbside recyclable shipping solutions.
